JacobP.LaubachMD

PubMed

• 34 citations
  Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation
  Jacob P. Laubach, Ping Fu, Xiaohong Jiang, Kelly H. Salter, Anil Potti
  Experimental Hematology. 2009-12-01
• 156 citations
  Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
  Jacalyn Rosenblatt, Irit Avivi, Baldev Vasir, Lynne Uhl, Nikhil C. Munshi
  Clinical Cancer Research. 2013-07-01
• 8 citations
  Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
  P G Richardson, C C Hofmeister, N S Raje, D S Siegel, S Lonial
  Leukemia. 2017-12-01

Abstracts/Posters

• Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refr...
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoprotein... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Debate: Should Everyone Receive Monoclonal Antibodies in First Relapse? Yes 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all